Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144228 · ClinicalTrials.gov registry record
Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
A clinical trial of Prostate Cancer (Diagnosis), sponsored by Duke University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07144228 is a study of Prostate Cancer (Diagnosis) that is actively recruiting participants, run by Duke University. The registered enrollment target is 300 participants, below the 824-participant average among 5 other Prostate Cancer (Diagnosis) trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07144228, a study of Prostate Cancer (Diagnosis), is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious disease. Currently, doctors rely on multiple tests such as PSA, MRI scans and biopsies to do the same evaluation. Researchers are trying to see if HeLP™ can be a safe and accurate alternative. The study is inviting men who are being seen for suspicion of prostate cancer (based on symptoms or previous lab results). If they agree to be in the study, the research team will take a sample of their blood at the time they are getting a repeat PSA test or having Imaging. The research test does not affect the care they are already receiving and takes 3 extra tubes of blood (\~3 tbsp). The research team is aiming to include 300 participants total. They believe 278 people are needed to confidently compare results between people with and without prostate cancer. They will do an interim analysis halfway through the study, once samples from 150 subjects have been collected. The research is considered low risk-no more uncomfortable or dangerous than a blood draw. There is a risk of loss of privacy, but researchers are taking strong steps to protect privileged information. That includes proper data handling, secure, storage, and making sure the study team is trained in research ethics.
Conditions Studied
Interventions
- DEVICE HeLP TM
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2028-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144228
The ClinicalTrials.gov registry entry for NCT07144228 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 5 other Prostate Cancer (Diagnosis) trials with a reported enrollment target (64% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which HeLP TM is the first listed.
NCT07144228 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07144228 about?
NCT07144228 is a clinical study titled "Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer". This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious disease. Currently, doctors rely on multiple tests such as PSA, MRI scans and biopsies to do the same e...
What is the current status of trial NCT07144228?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-03-11. Estimated completion is 2028-09-30.
What conditions does trial NCT07144228 study?
This clinical trial studies the following conditions: Prostate Cancer (Diagnosis).
What interventions are being tested in trial NCT07144228?
The interventions under investigation include: HeLP TM (DEVICE).
Who is sponsoring clinical trial NCT07144228?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144228 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Diagnosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
RECRUITING · Phase 1
-
Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe
RECRUITING · Phase 1
-
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
RECRUITING
-
Stockholm3 Validation Study in a Multi-Ethnic Cohort
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.